Another great #ESCCongress is over and thrilled to be part of an inspiring faculty speaking about when to offer genetic testing in myocarditis. Two years post-publication, our study continues to steer this rapidly evolving field 🇬🇧. @RBandH @ImperialNHLI @AJ_Fund_ @TheBHF

RT @momina_yazdani: Our research is only possible with the support of the amazing team at @AJ_Fund_. A small but mighty charity- you are an….

#SCMR2024 standing-room only for Prof Vanessa Ferreira highlighting our recent work and providing an excellent summary of when to consider genetics in myocarditis @SCMRorg @ImperialNHLI @RBandH #whyCMR

Is genetic testing in myocarditis ready for prime time? 🚨 1 in 13 patients in this population-representative study had underlying likely pathogenic DCM or ACM gene variants, building on previous smaller scale 🧬 studies #Cardiotwitter.

Looking forward to speaking about #myocarditis this evening at @RoySocMed with @AJ_Fund_🫀.

RT @MRC_LMS: New research from the Cardiovascular Genomics and Precision Medicine group led by @drjamesware has shown that one in 13 people….

🧬1 in 13 patients presenting with acute myocarditis had an underlying variant in a gene robustly linked to DCM or ACM that would be reported as 'likely pathogenic' in a patient with cardiomyopathy🫀. Read more about our study here, and 🔓 @CircAHA:

RT @AJ_Fund_: #SmallButMighty indeed we are! Our latest #myocarditis #research with @RBandH being featured on @American_Heart landing page….

RT @elliemquinn: Fantastic work @amritlota and team 👏👏👏 this highlights the importance of considering genetic testing in patients with #myo….

RT @AndrewJMDSilva: @amritlota @CircAHA @RBandH @ImperialNHLI @CVGenomics @TheBHF @AJ_Fund_ Brilliant work! Well done 👏 Too often patients….

We thank everyone involved at @RBandH @ImperialNHLI @TheBHF @AJ_Fund_ @MRC_LMS @wellcometrust @NHSDigital. A great collaboration with colleagues across the world, 🇬🇧🇳🇱🇪🇸🇺🇸🏴󠁧󠁢󠁳󠁣󠁴󠁿 @drjamesware @bp_halliday Sanjay Prasad, @HeymansStephane @dr_pavia @stuartacook1 & Leslie Cooper.

💟Incorporation of genetic testing should be considered in acute myocarditis, particularly with reduced LVEF, arrhythmia or family hx of cardiomyopathy, to inform risk stratification and clinical management, including the need for ongoing surveillance & family screening.

Why does this study matter?.💟It explains some of the wide heterogeneity in clinical outcomes in acute myocarditis .💟It supports the concept that genotype-positive individuals may remain phenotypically silent until the occurrence of an environmental trigger 😷💊💉.

In conclusion:.➡️1 in 13 patients with acute myocarditis had a likely pathogenic variant in a DCM or ACM gene.➡️Genotype-postive patients tended to have a worse clinical outcome.➡️This study highlights the potential role of genetic sequencing in acute myocarditis.

🔍The London cohort was representative of national myocarditis admissions confirmed via #NHSDigital. Of 2353 admissions due to myocarditis during the study period, 69% were men with median age 35 yrs. Women presented later in life (median age 52 yrs).

Overall, DSP truncating variants were the most prevalent genetic finding in young men presenting with chest pain and normal LVEF, and TTN truncating variants in those with heart failure and reduced LVEF:.#WhyCMR

Most prevalent gene variants:.🚨 TTN truncating variants were found in 7% of cases, all with LVEF <50%, vs 1% of controls (odds ratio 3.6; P=0.0116).🚨 Variants in ACM genes were found in 3% of cases vs 0.4% of controls (OR 8.2; P=0.001). This was driven predominantly by DSP-tv:

Overall, we found:.💥8% of patients with acute myocarditis (27/336) carried likely pathogenic 🧬variants in ACM or DCM genes vs <1% in healthy volunteers (p<0.0001).💔5-year all-cause mortality risk = 3.3% for genotype-negative vs 11.1% for genotype-positive patients (P=0.08).